Palo Alto, CA – According to filings with the U.S. Securities and Exchange Commission, Neumentum is raising $7,000,000.00 in a new round of investment. Sources indicate as part of senior management Chief Executive Officer, Scott Shively played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Neumentum

Neumentum is developing and plans to commercialize products that have the potential to effectively treat pain, without the risks of abuse, misuse and diversion seen with opioid analgesics. Neumentum’s lead product candidate, NTM-001 (novel, alcohol-free formulation of ketorolac in a pre-mixed bag for continuous IV infusion), has the potential to treat moderately severe acute pain that requires analgesia at the opioid level for up to 24 hours, usually in a postoperative setting, and to reduce the need for opioids.

To learn more about Neumentum, visit http://neumentum.com/

Contact:
Scott Shively, Chief Executive Officer
(833) 638-7246
scottshively@neumentum.com
https://www.linkedin.com/in/r-scott-shively/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved